Cancer Screening (Cervix, Breast)

HE4

Human Papillomavirus High Carcinogenic Risk (Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), DNA, without genotyping [Real-time PCR]

Human Papillomavirus High Carcinogenic Risk (Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), DNA Genotyping [Real-Time PCR]

Human Papillomavirus Low (HPV 6, 11, 44) and High (HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) Carcinogenic Risk, DNA (Detection, Genotyping and Quantitative Determination) [Real-time PCR, Russia]

Human Papillomavirus 16/18 (HPV 16/18), DNA (detection, genotyping and quantitative determination) [real-time PCR]

Human Papillomavirus High Carcinogenic Risk (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), DNA quantitative, screening with determination of possible virus integration into the genome [real-time PCR]

Female Oncology

Risk of early development of breast and ovarian cancer

Cancer antigen CA 15-3

Cancer antigen CA 125